News Releases

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- BOSTON --(BUSINESS WIRE)--Dec. 16, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of

BOSTON --(BUSINESS WIRE)--Nov. 21, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an

– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study designs of CONNECT program optimized based on encouraging results from early cohort – – Strengthened leadership team with addition of Paul Streck , MD, MBA, as head of R&D – BOSTON

BOSTON --(BUSINESS WIRE)--Nov. 4, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will

BOSTON --(BUSINESS WIRE)--Oct. 8, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will

BOSTON --(BUSINESS WIRE)--Sep. 19, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher

BOSTON --(BUSINESS WIRE)--Aug. 20, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an

BOSTON --(BUSINESS WIRE)--Aug. 20, 2024-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of

– CONNECT1-EDO51 clinical trial data from low-dose cohort were reported in July. PGN-EDO51 at 5 mg/kg was well tolerated, achieved mean exon skipping levels of 2.15%, mean muscle-adjusted dystrophin production increase of 0.70% from baseline and mean absolute dystrophin production increase of 0.26%

– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg